文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

纳武利尤单抗联合他克莫司和泼尼松±伊匹木单抗治疗肾移植受者晚期皮肤癌

Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
PubMed 文献 · J Clin Oncol · 2024-01-22

这项前瞻性临床试验在晚期黑色素瘤、基底细胞癌、皮肤鳞状细胞癌或默克尔细胞癌的成人肾移植受者中测试纳武利尤单抗+他克莫司+泼尼松±伊匹木单抗。8例可评估患者均未达到主要终点,全部出现疾病进展,1例发生治疗相关移植物丢失;后续6例接受伊匹木单抗+纳武利尤单抗者中2例完全缓解。作者认为他克莫司+泼尼松提供的移植物保护不足,供体来源游离DNA升高可比血肌酐升高更早提示排斥反应。

要点

  • 8例可评估肾移植受者接受纳武利尤单抗+他克莫司+泼尼松后均出现疾病进展,1例发生治疗相关移植物丢失。
  • 后续6例接受伊匹木单抗+纳武利尤单抗者中,最佳总体反应为2例完全缓解、4例疾病进展,其中各1例发生移植物丢失。
  • 供体来源游离DNA升高可比血肌酐升高早10天和15天提示治疗相关移植物排斥。

核心结论

  • 在多数晚期皮肤癌肾移植受者中,他克莫司+泼尼松提供的移植物保护不足,并损害纳武利尤单抗±伊匹木单抗给药后免疫介导的肿瘤消退。
  • 供体来源游离DNA水平升高可比血肌酐升高更早提示治疗相关移植物排斥。

研究设计与样本

  • 前瞻性临床试验,纳入晚期黑色素瘤或基底细胞癌、皮肤鳞状细胞癌或默克尔细胞癌的成人肾移植受者。
  • 免疫抑制标准化为他克莫司(血清谷浓度2-5 ng/mL)+泼尼松5 mg每日一次,随后纳武利尤单抗480 mg静脉注射每4周一次。
  • 主要复合终点为16周时按RECIST v1.1达到部分或完全肿瘤缓解或疾病稳定且无移植物丢失。
  • 疾病进展患者可接受伊匹木单抗1 mg/kg静脉注射+纳武利尤单抗3 mg/kg每3周一次×4次,随后纳武利尤单抗。
  • 约每2周检测一次供体来源游离DNA水平,作为移植物排斥的潜在预测指标。

主要发现

  • 8例可评估患者中无人达到试验主要终点,全部8例在纳武利尤单抗+他克莫司+泼尼松治疗中发生疾病进展,1例发生治疗相关移植物丢失。
  • 6例后续接受伊匹木单抗+纳武利尤单抗+他克莫司+泼尼松,最佳总体反应为2例完全缓解(其中1例发生移植物丢失)和4例疾病进展(其中1例发生移植物丢失)。
  • 8例纳武利尤单抗前肿瘤活检中7例浸润免疫细胞稀少;5例纳武利尤单抗治疗中活检中2例显示中度免疫浸润,这两例患者后来对伊匹木单抗+纳武利尤单抗达到完全缓解。
  • 3例发生治疗相关移植物丢失的患者中,2例供体来源游离DNA升高分别发生在血肌酐升高前10天和15天。

临床怎么用

  • 作者结论认为,在多数晚期皮肤癌肾移植受者中,他克莫司+泼尼松提供的移植物保护不足并损害纳武利尤单抗±伊匹木单抗后免疫介导的肿瘤消退。
  • 作者报告供体来源游离DNA水平升高可比血肌酐升高更早提示治疗相关移植物排斥。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cancer-related mortality rates among kidney transplant recipients (KTR) are high, but these patients have largely been excluded from trials of immune checkpoint inhibitors because of immunosuppression and risk of treatment-related allograft loss (TRAL). We conducted a prospective clinical trial testing nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) ± ipilimumab (IPI) in KTR with advanced cutaneous cancers. METHODS: Adult KTR with advanced melanoma or basal, cutaneous squamous, or Merkel cell carcinomas were eligible. Immunosuppression was standardized to TACRO (serum trough 2-5 ng/mL) + PRED 5 mg once daily. Patients then received NIVO 480 mg IV once every 4 weeks. The primary composite end point was partial or complete (tumor) response (CR) or stable disease per RECIST v1.1 without allograft loss at 16W. Patients with progressive disease (PD) could receive IPI 1 mg/kg IV + NIVO 3 mg/kg once every 3 weeks × 4 followed by NIVO. Donor-derived cell-free DNA (dd-cfDNA) levels were measured approximately once every 2 weeks as a potential predictor of allograft rejection. RESULTS: Among eight evaluable patients, none met the trial's primary end point. All eight patients experienced PD on NIVO + TACRO + PRED; TRAL occurred in one patient. Six patients then received IPI + NIVO + TACRO + PRED. Best overall responses: two CR (one with TRAL) and four PD (one with TRAL). In total, 7 of 8 pre-NIVO tumor biopsies contained a paucity of infiltrating immune cells. In total, 2 of 5 on-NIVO biopsies demonstrated moderate immune infiltrates; both patients later experienced a CR to IPI + NIVO. In 2 of 3 patients with TRAL, dd-cfDNA elevations occurred 10 and 15 days before increases in serum creatinine. CONCLUSION: In most KTR with advanced skin cancer, TACRO + PRED provides insufficient allograft protection and compromises immune-mediated tumor regression after administration of NIVO ± IPI. Elevated dd-cfDNA levels can signal treatment-related allograft rejection earlier than rises in serum creatinine.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Schenk KM, Deutsch JS, Chandra S, et al. Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers. J Clin Oncol. 2024. PMID: 38252910. doi:10.1200/JCO.23.01497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。